Sunday, July 23, 2023 | The Latest Research, Commentary, And News From Health Affairs
Dear John,
This week, we published an ahead-of-print article from Julia Dennett and Gregg Gonsalves examining how the
marketing of OxyContin's in 1996 led to serious long-term health problems even today.
Their study compares outcomes between states with high and low levels of exposure to early OxyContin marketing both before and after the 2010 reformulation of OxyContin.
Dennett and Gonsalves conclude that "exposure to initial OxyContin marketing statistically significantly increased fatal synthetic opioid-related overdose rates; incidence of acute hepatitis A, hepatitis B, and hepatitis C; and infective endocarditis-related mortality rates after the 2010 OxyContin reformulation."
These findings suggest that OxyContin marketing in 1996 is related to adverse long-term health outcomes over twenty-five years later.
Supported by CVS Health and featuring health equity experts as they examine private-sector initiatives and responsibility to advance health equity, the series includes articles exploring private-sector efforts to challenge injustices in health care.
In an article in the series, Yvonne Commodore-Mensah and co-authors review private-public partnerships to advance cardiovascular health equity.
Editor-in-Chief Alan Weil interviews Yanlei Ma from Harvard University on her recently published paper examining trends in D-SNP look alike plan enrollment.
Health Affairs is the leading peer-reviewedjournalat the intersection of health, health care, and policy. Published monthly by Project HOPE, the journal is available in print and online. Late-breaking
content is also found through healthaffairs.org, Health Affairs Today, and Health Affairs Sunday Update.
Project HOPE is a global health and humanitarian relief organization that places power in the hands of local health care workers to save lives across the globe. Project HOPE has published Health Affairs since 1981.
